The DEVOTE (Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients With Type 2 Diabetes at High Risk of Cardiovascular Events) trial randomized 7637 individuals with type 2 diabetes to insulin degludec or insulin glargine. Here, INS is linked to type 2 diabetes mellitus.